Richard Frank, MD
Hematology & Oncology · Norwalk, CTNPI 1174515803
Payments from drug & device makers
Across 416 payments — averaging $7834.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1.5M
- Pfizer$1.5M
- EMD Serono, Inc.$112K
- Morphosys AG$49K
- Janssen Research & Development, LLC$46K
- Bristol Myers Squibb$22K
- plus $63K from 29 others
Across 7 payments — averaging $504.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$4K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 34 | $1,496,187 |
| Pfizer | 91 | $1,471,243 |
| EMD Serono, Inc. | 119 | $112,036 |
| Morphosys AG | 1 | $48,693 |
| Janssen Research & Development, LLC | 5 | $45,723 |
| Bristol Myers Squibb | 26 | $22,266 |
| Alkermes, Inc. | 11 | $14,213 |
| Incyte Corporation | 9 | $13,452 |
| Genentech, Inc. | 3 | $13,357 |
| Pharmacyclics LLC, An Abbvie Company | 7 | $13,012 |
| Ares Trading SA | 13 | $6,203 |
| Novartis | 14 | $818 |
| AstraZeneca | 4 | $423 |
| Array Biopharma Inc | 11 | $248 |
| AbbVie | 11 | $246 |
| Merck | 16 | $243 |
| Gilead | 8 | $192 |
| Johnson & Johnson | 4 | $82 |
| GSK | 3 | $72 |
| Genentech USA, Inc. | 3 | $61 |
| Sanofi | 3 | $58 |
| Jazz Pharmaceuticals Inc. | 3 | $53 |
| Lilly USA, LLC | 3 | $50 |
| E.r. Squibb & Sons, L.L.C. | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Mirati Therapeutics, Inc. | 1 | $35 |
| Astellas Pharma US Inc | 1 | $30 |
| ADC Therapeutics America, Inc. | 1 | $28 |
| Eisai Inc. | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Legend Biotech USA Inc. | 1 | $17 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $15 |
| Pharmaessentia USA Corporation | 1 | $14 |
| Boehringer Ingelheim | 1 | $11 |
How this compares
$3,259,232 in reported general payments places this provider in the 95th percentile of 163 hematology & oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Norwalk
- George ZahrahNorwalk$645K
- Lisa PhuongNorwalk$216K
- Richard ZelkowitzNorwalk$87K
- Amer ZeidanNew Haven$15.5M
- Nataliya UbohaNew Haven$13.3M
- Michael CecchiniNew Haven$7.8M
- Tarsheen SethiNew Haven$2.6M
- Terri ParkerNew Haven$2.4M
- Iris IsufiNew Haven$2.1M
- Jeremy KortmanskyHamden$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.